Related Experiment Video
Updated: Oct 4, 2025
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.6K
Adoptive cell therapies in thoracic malignancies.
Julie Lasvergnas1,2, Marie Naigeon3,4,5, Kader Chouahnia1
1Medical and Thoracic Oncology Department, Hopital Avicenne, AP-HP, Bobigny, France.
Cancer Immunology, Immunotherapy : CII
|February 7, 2022
Summary
Adoptive cell therapy (ACT) shows promise for thoracic cancers like lung cancer and mesothelioma, potentially overcoming resistance to current immunotherapies. Combining ACT with other treatments may improve patient outcomes.
Area of Science:
- Oncology
- Immunology
- Thoracic Malignancies
Background:
- Immunotherapy, particularly immune checkpoint blockers (ICBs), has shown promise in thoracic malignancies such as non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), and malignant pleural mesothelioma (MPM).
- A significant limitation is the widespread resistance to ICBs, often due to non-immunogenic tumors, immunosuppressive tumor microenvironments, or impaired immune cell trafficking.
- Adoptive cell therapy (ACT) presents a potential strategy to overcome these challenges by delivering functional immune cells directly to the tumor site.
Purpose of the Study:
- To review the current landscape of ACT strategies for thoracic malignancies.
- To discuss the advantages, limitations, and future directions of various ACT approaches.
- To explore the potential of combining ACT with existing treatments like ICBs, chemotherapy, and radiotherapy.
Main Methods:
- Review of existing literature on ACT in thoracic cancers.
- Discussion of different ACT modalities including lymphokine-activated killer (LAK) cells, cytokine-induced killer (CIK) cells, natural killer (NK) cells, dendritic cell (DC) vaccines, tumor-infiltrating lymphocytes (TILs), T-cell receptor (TCR) engineering, and chimeric antigen receptor (CAR) T-cells.
- Analysis of early-phase clinical trial data and future perspectives.
Main Results:
- Various ACT approaches are under investigation for thoracic cancers, each with unique mechanisms and potential benefits.
- Early trials indicate that ACT can potentially enhance anti-tumor immunity in patients resistant to conventional therapies.
- Combinatorial strategies involving ACT alongside ICBs, chemotherapy, or radiotherapy are being explored to improve efficacy.
Conclusions:
- ACT holds significant promise for improving treatment outcomes in thoracic malignancies, especially for patients resistant to current immunotherapies.
- Further research and clinical trials are necessary to overcome existing limitations and optimize ACT protocols.
- Combination therapies integrating ACT with established treatments represent a promising future direction for thoracic cancer management.
Related Concept Videos
01:27Tumor Immunotherapy
711
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
01:21Stem Cell Therapy for Tissue Regeneration
4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K